Cynosure (Nasdaq: CYNO ) is expected to report Q1 earnings on April 30. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Cynosure's revenues will grow 13.7% and EPS will expand 116.7%.
The average estimate for revenue is $38.8 million. On the bottom line, the average EPS estimate is $0.13.
Last quarter, Cynosure chalked up revenue of $42.7 million. GAAP reported sales were 25% higher than the prior-year quarter's $34.1 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.27. GAAP EPS of $0.26 for Q4 were 189% higher than the prior-year quarter's $0.09 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 58.1%, 180 basis points better than the prior-year quarter. Operating margin was 9.9%, 70 basis points better than the prior-year quarter. Net margin was 9.5%, 630 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $190.5 million. The average EPS estimate is $0.83.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 370 members out of 385 rating the stock outperform, and 15 members rating it underperform. Among 86 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 79 give Cynosure a green thumbs-up, and seven give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Cynosure is buy, with an average price target of $34.00.
Is Cynosure the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Cynosure to My Watchlist.